Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00009919 · ClinicalTrials.gov registry record · Phase 2
SU5416 in Treating Patients With Metastatic Kidney Cancer That Has Not Responded to Previous Treatment
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Terminated
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
NCT00009919: Clinical Trial Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00009919 is a Phase 2 study that was terminated before completion, run by National Cancer Institute (NCI). The registered enrollment target is 50 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00009919, a Phase 2 study, was terminated before completion, sponsored by National Cancer Institute (NCI).
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
Study Summary
Phase II trial to study the effectiveness of SU5416 in treating patients who have metastatic kidney cancer that has not responded to previous therapy with interleukin-2. SU5416 may stop the growth of kidney cancer by stopping blood flow to the tumor
Interventions
- DRUG semaxanib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2000-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00009919
The ClinicalTrials.gov registry entry for NCT00009919 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which semaxanib is the first listed.
NCT00009919 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00009919 about?
NCT00009919 is a clinical study titled "SU5416 in Treating Patients With Metastatic Kidney Cancer That Has Not Responded to Previous Treatment". Phase II trial to study the effectiveness of SU5416 in treating patients who have metastatic kidney cancer that has not responded to previous therapy with interleukin-2. SU5416 may stop the growth of kidney cancer by stopping blood flow to the tumor
What is the current status of trial NCT00009919?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2000-12.
What interventions are being tested in trial NCT00009919?
The interventions under investigation include: semaxanib (DRUG).
Who is sponsoring clinical trial NCT00009919?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.